FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994810306> ?p ?o ?g. }

• W1994810306 abstract "Malignant melanoma has the highest fatality among all skin cancers. No current treatment significantly enhances survival once metastasis is established. Previous studies have shown that E2F1, a transcription factor, is over-expressed in melanoma cells. However, the mechanism through which E2F1 is elevated remains unknown. E2F1 is known to be involved in many important biological processes, including cell cycle progression, DNA damage, DNA repair, differentiation, development, autophagy and apoptosis. This underscores the importance of E2F1 in carcinogenesis. Normally in late S phase, E2F1 is recognized by the E3 ligase p45 SKP2 and undergoes ubiquitination and finally degradation in 26S proteasome. Our overall hypothesis is that E2F1 escapes proteasomal degradation in melanoma cells due to changes in post-translational modification. In this study we have used melanoma cells of increasing disease progression. Our results show that although the primary melanoma cells have high level of E2F1 message and protein, it is unstable. On the other hand the more metastatic melanoma cells have low levels of E2F1 which is however very stable. Consistent with this result, post-translational modification of E2F1 including the phosphorylation at Serine 337 and the acetylation at Lysine 117 increase with melanoma progression, which suggests that these post-translational modification sites might play an important role in stabilization of E2F1 and keep it functionally active in the more metastatic cell lines. E2F1 knockdown data also shows that E2F1 KD can inhibit cell proliferation in early stage melanoma cells but not in the more metastatic cells, which also suggest that inhibition of post-translational modifications and stability of E2F1 may be a more effective way to inhibit melanoma progression to more advanced stages. Abrogation of acetylation is expected to cause E2F1 protein instability. On the other hand, if acetylation is potentiated, the stabilized E2F1 will continue to promote progression through the cell cycle. We are currently testing whether the ectopic expression of the continuously acetylated E2F1 protein can rescue proliferation inhibition caused by E2F1 down-regulation, and drive metastasis and a mutant E2F1 with abrogated acetylation can block rescue of the proliferation inhibition in the E2F1 down-regulated melanoma cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4208. doi:1538-7445.AM2012-4208" @default.
• W1994810306 created "2016-06-24" @default.
• W1994810306 creator A5002100171 @default.
• W1994810306 creator A5055705058 @default.
• W1994810306 date "2012-04-15" @default.
• W1994810306 modified "2023-09-25" @default.
• W1994810306 title "Abstract 4208: Post-translational modification of E2F1 in malignant melanoma" @default.
• W1994810306 doi "https://doi.org/10.1158/1538-7445.am2012-4208" @default.
• W1994810306 hasPublicationYear "2012" @default.
• W1994810306 type Work @default.
• W1994810306 sameAs 1994810306 @default.
• W1994810306 citedByCount "0" @default.
• W1994810306 crossrefType "proceedings-article" @default.
• W1994810306 hasAuthorship W1994810306A5002100171 @default.
• W1994810306 hasAuthorship W1994810306A5055705058 @default.
• W1994810306 hasConcept C121608353 @default.
• W1994810306 hasConcept C183022183 @default.
• W1994810306 hasConcept C190283241 @default.
• W1994810306 hasConcept C2777658100 @default.
• W1994810306 hasConcept C29537977 @default.
• W1994810306 hasConcept C502942594 @default.
• W1994810306 hasConcept C54355233 @default.
• W1994810306 hasConcept C555283112 @default.
• W1994810306 hasConcept C71924100 @default.
• W1994810306 hasConcept C86803240 @default.
• W1994810306 hasConceptScore W1994810306C121608353 @default.
• W1994810306 hasConceptScore W1994810306C183022183 @default.
• W1994810306 hasConceptScore W1994810306C190283241 @default.
• W1994810306 hasConceptScore W1994810306C2777658100 @default.
• W1994810306 hasConceptScore W1994810306C29537977 @default.
• W1994810306 hasConceptScore W1994810306C502942594 @default.
• W1994810306 hasConceptScore W1994810306C54355233 @default.
• W1994810306 hasConceptScore W1994810306C555283112 @default.
• W1994810306 hasConceptScore W1994810306C71924100 @default.
• W1994810306 hasConceptScore W1994810306C86803240 @default.
• W1994810306 hasLocation W19948103061 @default.
• W1994810306 hasOpenAccess W1994810306 @default.
• W1994810306 hasPrimaryLocation W19948103061 @default.
• W1994810306 hasRelatedWork W1521495933 @default.
• W1994810306 hasRelatedWork W1633623868 @default.
• W1994810306 hasRelatedWork W168129332 @default.
• W1994810306 hasRelatedWork W1875678032 @default.
• W1994810306 hasRelatedWork W1966147273 @default.
• W1994810306 hasRelatedWork W2023842642 @default.
• W1994810306 hasRelatedWork W2032948236 @default.
• W1994810306 hasRelatedWork W2055434824 @default.
• W1994810306 hasRelatedWork W2071386873 @default.
• W1994810306 hasRelatedWork W2095469838 @default.
• W1994810306 hasRelatedWork W2193005545 @default.
• W1994810306 hasRelatedWork W2271110059 @default.
• W1994810306 hasRelatedWork W2319548350 @default.
• W1994810306 hasRelatedWork W2329189953 @default.
• W1994810306 hasRelatedWork W2334840060 @default.
• W1994810306 hasRelatedWork W2484808876 @default.
• W1994810306 hasRelatedWork W2622458967 @default.
• W1994810306 hasRelatedWork W2762521153 @default.
• W1994810306 hasRelatedWork W3024557408 @default.
• W1994810306 hasRelatedWork W3095941576 @default.
• W1994810306 isParatext "false" @default.
• W1994810306 isRetracted "false" @default.
• W1994810306 magId "1994810306" @default.
• W1994810306 workType "article" @default.